Francesc Gòdia is a Full Professor of Chemical Engineering at Universitat Autònoma de Barcelona (UAB) since 1993. Teaching activities in Biotechnology and Chemical Engineering. Coordinator of the Biotechnology Doctoral Program at UAB. His research activity is focussed on Regenerative Technology for Life Support in Space and Animal Cell Technology for the production of biopharmaceuticals, recombinant…
What is the activity of your company? Cereal Docks Group is a family business generating eight hundred million euros of revenues. Our core business is focused on the primary transformation: transforming agricultural raw materials (like soy, sunflower and rapeseed) into ingredients like cakes, oils and lecithins mainly for feed and food industries but also for…
The YEBN has had the pleasure of interviewing two members of the Nature Italy team, Joffrey Planchard and Nicola Nosengo. Joffrey Planchard is Strategic Partnerships Manager at Nature Research in charge of relationships with institutions in the UK, Western and Southern Europe and Africa. He has 20 years of experience studying and working in the…
I was born and raised in Greece. I hold a PhD in Conservation Science from the University of Bologna in Italy and diploma in Civil Engineering (5-year studies) from the Aristotle University of Thessaloniki in Greece. I have worked as a research and teaching fellow in Italy, Hungary and Cyprus, with scientific contributions to the design…
Laura Moro, Ph.D. As you all know, this year Nobel Prize in Chemistry was recently awarded to Prof. Emmanuelle Charpentier and Prof. Jennifer A. Doudna who discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. We spoke with Lorena de Oñate, PhD, a postdoctoral researcher from Barcelona currently working at the Innovative Genomics…
Brief Introduction about yourself and the project (TATAMI) I am a scientific researcher looking for new therapeutic approaches for neuromuscular diseases. In this project particularly we are developing a novel therapeutic strategy for myotonic dystrophy based on blocking specific small RNAs or microRNA with antisense oligonucleotides, or anti-miRs. Tell us about you implication in the…
Brief Introduction about yourself and ARTHEx Biotech I have been working as a postdoctoral researcher in the department of Genetics in the University of Valencia, dedicated mainly to deciphering the pathomechanisms of Myotonic Dystrophy disease and finding new therapeutic targets for the disease. ARTHEx Biotech S.L is a spin-off company of the University of Valencia…
